| Identification | Back Directory | [Name]
Kaempferol 3-arabinofuranoside | [CAS]
5041-67-8 | [Synonyms]
Juglanin
Juglanin【Juglans】
Kaempferol 3-arabinoside
Kaempferol 3-arabinofuranoside
Kaempferol 3-O-alpha-L-arabinofuranoside
3-[(α-L-Arabinofuranosyl)oxy]-4',5,7-trihydroxyflavone
3-(α-L-Arabinofuranosyloxy)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one
4H-1-Benzopyran-4-one,3-(a-L-arabinofuranosyloxy)-5,7-dihydroxy-2-(4-hydroxyphenyl)-
4H-1-Benzopyran-4-one, 3-(α-L-arabinofuranosyloxy)-5,7-dihydroxy-2-(4-hydroxyphenyl)- | [Molecular Formula]
C20H18O10 | [MDL Number]
MFCD26406180 | [MOL File]
5041-67-8.mol | [Molecular Weight]
418.35 |
| Chemical Properties | Back Directory | [Melting point ]
230-231℃ (ethanol ) | [Boiling point ]
803.5±65.0 °C(Predicted) | [density ]
1.76±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Methanol : 16.67 mg/mL (39.85 mM) | [form ]
Solid | [pka]
6.20±0.40(Predicted) | [color ]
White to yellow | [InChI]
InChI=1/C20H18O10/c21-7-13-15(25)17(27)20(29-13)30-19-16(26)14-11(24)5-10(23)6-12(14)28-18(19)8-1-3-9(22)4-2-8/h1-6,13,15,17,20-25,27H,7H2/t13-,15-,17+,20?/s3 | [InChIKey]
POQICXMTUPVZMX-XQAOVFCONA-N | [SMILES]
C1(C2=CC=C(O)C=C2)OC2=C(C(=CC(=C2)O)O)C(=O)C=1OC1O[C@H](CO)[C@@H](O)[C@@H]1O |&1:23,26,28,r| |
| Hazard Information | Back Directory | [Uses]
Juglanin inhibits the proliferation of breast cancer cell in a dose- and time-dependent manner and presents less cytotoxic against the normal cells. It is a JNK activator. | [Definition]
ChEBI: Kaempferol 3-arabinofuranoside is a member of flavonoids and a glycoside. | [in vivo]
Juglanin (10-20 mg/kg, i.p., daily, 7 days) inhibits growth of human breast cancer xenograft in a tumor-transplanted mouse model[1].
Juglanin (10-30 mg/kg, i.p., 5 times weekly) ameliorates neuroinflammation-related memory impairment and neurodegeneration through impeding TLR4/NF-κB in C57BL6 male mice[2].
Juglanin (80 mg/kg, i.g., daily, 21 days) protects against bleomycin (BLM, HY-108345)-induced lung injury by inhibiting fibrosis in C57BL/6 male mice[3].
| Animal Model: | Tumor-transplanted mouse model [1] | | Dosage: | 10-20 mg/kg | | Administration: | Intraperitoneal injection (i.p.), daily, 7 days | | Result: | Increased levels of cleaved Caspase-9 and Caspase-3, LC3BI, LC3BII and phosphorylated JNK.
Increased dead cells and apoptosis proportion in juglanin-treated tumor tissues.
Increase in mean areas that stained positively cleaved Caspase-3 in juglanin-treated tumor tissues.
|
| Animal Model: | C57BL6 male mice[2] | | Dosage: | 10-30 mg/kg | | Administration: | Intraperitoneal injection (i.p.), 5 times weekly | | Result: | Increased number of platform crossings and expanded time in target quadrant.
Decreased the expression level of α-synuclein, pro-inflammatory cytokines (IL-1β, TNF-α, IL-18 and COX-2), TLR-4, MyD88, CD14, Aβ, phosphorylation of Tau, Ibal and neurotrophic factor (BDNF).
Reversed LPS-triggered effect on synaptic markers, up-regulating the expression of SYP, PSD-95 and SNAP-25.
Restored TH levels in the hippocampus of mice in a dose-dependent manner.
Decreased p-IKKα, p-IκBα and p-NF-κB levels combinated with LPS.
Decreased the GFAP-positive cells.
|
| Animal Model: | C57BL/6 male mice[3] | | Dosage: | 80 mg/kg | | Administration: | i.g., daily, 1-21 days | | Result: | Improved the survial rate of the BLM (HY-108345)-treated mice.
Decreased the expression of BALF, CXCL1, IL-6, TNF-α, MPO activity, TGF-β1, and its down-streaming proteins (fibronectin/MMP-9/α-SMA/collagen I)
Reduced the number of total cells, neutrophils and macrophages in BALF.
|
| [IC 50]
JNK |
|
|